News blog

N4 Pharma

  • BY: Andrew Hore |
  • POSTED: 22/04/2019 |

N4 Pharma says that recent formulation work for Nuvec has demonstrated inconsistencies with previous studies and the share price has nearly halved in the past fortnight. 

Nuvec is a potential nanoparticle drug delivery technology. The in vitro tests produced positive results but this was not replicated in in vivo tests. Further experiments will be undertaken in order to define protocols and methodology to ensure that the tests are standardised.

News about further studies should be available by the end of the summer.

There should be enough cash to last until the end of 2019, thanks to a recent £1m placing at 10p a share.  The current share price is 4.15p.

© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

News Blog
All micro news

Quoted Micro 20 May 2019

Continue reading... | 20/05/2019

Tricorn Group

Engineer Tricorn has invested $50,000 in a fully operational powder coat and wet spray painting line in Georgia.

Continue reading... | 20/05/2019

LiDCO Group

Patient monitoring equipment developer and supplier LiDCO Group says that first quarter trading was better than expected. 

Continue reading... | 20/05/2019

Quoted Micro 13 May 2019

Continue reading... | 13/05/2019

All micro news

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds